Literature DB >> 22661251

Low yield of significant findings on endoscopic retrograde cholangiopancreatography in patients with pancreatobiliary pain and no objective findings.

Timothy D Imler1, Stuart Sherman, Lee McHenry, Evan L Fogel, James L Watkins, Glen A Lehman.   

Abstract

BACKGROUND: Due to the challenging nature of the type III sphincter of the Oddi dysfunction (SOD) patient, the suspected low diagnostic yield from endoscopic retrograde cholangiopancreatography (ERCP), the high complication rate, and the potential for litigation it is surprising that diagnostic ERCP continues to be performed in this patient population. AIMS: The purpose of this study was to determine the incidence of significant findings on ERCP alone in patients with disabling abdominal pain of suspected pancreatobiliary origin and no objective findings.
METHODS: Entry criteria of this study included: (1) ERCP with attempt at visualization of both the biliary tree and pancreatic duct, (2) suspected of having abdominal pain of pancreatobiliary origin, (3) biliary or pancreatic type III by the modified Geenen-Hogan classification, (4) never undergone sphincterotomy, (5) attempted manometry of both sphincters. A total of 265 patients met entry criteria.
RESULTS: Significant findings were found in seven patients (2.6 %): choledococoele (1), anomalous pancreatobiliary ductal union (2), mild-moderate chronic pancreatitis (2), and pancreatic duct filling defect suspicious for IPMN (2). Potentially significant in 25 patients (9.4 %) were: equivocal chronic pancreatitis (1), incomplete (4) and complete pancreas divisum (20). SOD was diagnosed in 77.7 %. 11.3 % had undergone a previous diagnostic ERCP.
CONCLUSION: ERCP in this high-risk population requires detailed informed consent, availability of SOM to increase the diagnostic yield, and skills in placing prophylactic pancreatic stents. It is our belief that patients without objective findings of pancreatobiliary disease that would explain their subjective complaints should not undergo diagnostic ERCP.

Entities:  

Mesh:

Year:  2012        PMID: 22661251     DOI: 10.1007/s10620-012-2250-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Complications of diagnostic and therapeutic ERCP: a prospective multicenter study.

Authors:  E Masci; G Toti; A Mariani; S Curioni; A Lomazzi; M Dinelli; G Minoli; C Crosta; U Comin; A Fertitta; A Prada; G R Passoni; P A Testoni
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

2.  Complications of ERCP.

Authors:  J Shawn Mallery; Todd H Baron; Jason A Dominitz; Jay L Goldstein; William K Hirota; Brian C Jacobson; Jonathan A Leighton; Hareth M Raddawi; John J Varg; J Patrick Waring; Robert D Fanelli; Jo Wheeler-Harbough; Glenn M Eisen; Douglas O Faigel
Journal:  Gastrointest Endosc       Date:  2003-05       Impact factor: 9.427

Review 3.  Biliary scintigraphy versus sphincter of Oddi manometry in patients with post-cholecystectomy pain: is it time to disregard the scan?

Authors:  James Toouli
Journal:  Curr Gastroenterol Rep       Date:  2005-05

4.  Predictors of outcomes after biliary and pancreatic sphincterotomy for sphincter of oddi dysfunction.

Authors:  Martin L Freeman; Muzaffar Gill; Carol Overby; Ye-Ying Cen
Journal:  J Clin Gastroenterol       Date:  2007-01       Impact factor: 3.062

5.  Analysis of 59 ERCP lawsuits; mainly about indications.

Authors:  Peter B Cotton
Journal:  Gastrointest Endosc       Date:  2006-03       Impact factor: 9.427

6.  Cholecystokinin-Stimulated mebrofenin (99mTc-Choletec) hepatobiliary scintigraphy in asymptomatic postcholecystectomy individuals: assessment of specificity, interobserver reliability, and reproducibility.

Authors:  B C Pineau; W L Knapple; K M Spicer; L Gordon; M Wallace; W S Hennessy; R H Hawes; P B Cotton
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

7.  Effects of meperidine on the pancreatic and biliary sphincter.

Authors:  S Sherman; K Gottlieb; M F Uzer; M T Smith; Q E Khusro; D T Earle; R L Brunelle; R H Hawes; G A Lehman
Journal:  Gastrointest Endosc       Date:  1996-09       Impact factor: 9.427

8.  The diagnostic yield of ERCP in the investigation of unexplained abdominal pain.

Authors:  W S Ruddell; D J Lintott; A T Axon
Journal:  Br J Surg       Date:  1983-02       Impact factor: 6.939

Review 9.  Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Martin L Freeman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-11       Impact factor: 11.382

Review 10.  Adverse outcomes of endoscopic retrograde cholangiopancreatography: avoidance and management.

Authors:  Martin L Freeman
Journal:  Gastrointest Endosc Clin N Am       Date:  2003-10
View more
  4 in total

1.  Quality indicators for ERCP.

Authors:  Douglas G Adler; John G Lieb; Jonathan Cohen; Irving M Pike; Walter G Park; Maged K Rizk; Mandeep S Sawhney; James M Scheiman; Nicholas J Shaheen; Stuart Sherman; Sachin Wani
Journal:  Am J Gastroenterol       Date:  2014-12-02       Impact factor: 10.864

Review 2.  How to measure quality in endoscopic retrograde cholangiopancreatography (ERCP).

Authors:  Alexander Krumov Katzarov; Zdravko Ivanov Dunkov; Ivan Popadiin; Krum Sotirov Katzarov
Journal:  Ann Transl Med       Date:  2018-07

Review 3.  Sphincter of Oddi dysfunction Type III: New studies suggest new approaches are needed.

Authors:  C Mel Wilcox
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

Review 4.  Advances in motility testing--current and novel approaches.

Authors:  Albert J Bredenoord; André J P M Smout
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-05-07       Impact factor: 46.802

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.